Epilepsy Research
Volume 77, Issue 2 , Pages 75-84 , December 2007

Effects of nociceptin on the spread and seizure activity in the rat amygdala kindling model: Their correlations with 3H-leucyl-nociceptin binding

  • Liliana Carmona-Aparicio

      Affiliations

    • Department of Pharmacobiology, Center of Research and Advanced Studies, Mexico City, Mexico
    • ,
  • Fernando Peña

      Affiliations

    • Department of Pharmacobiology, Center of Research and Advanced Studies, Mexico City, Mexico
    • ,
  • Anna Borsodi

      Affiliations

    • Biological Research Center of the Hungarian Academy of Sciences, Szeged, Hungary
    • ,
  • Luisa Rocha

      Affiliations

    • Department of Pharmacobiology, Center of Research and Advanced Studies, Mexico City, Mexico
    • Corresponding Author InformationCorresponding author. Tel.: +52 55 5061 2859; fax: +52 55 5061 2863.

Received 1 June 2007 ,Revised 15 August 2007 ,Accepted 30 August 2007.

References 

  1. Ackermann RF, Chugani HT, Handforth A, Moshé S, Caldecott-Hazard S, Engel JJ. Autoradiographic studies of cerebral metabolism and blood flow in rat amygdala kindling. In:  Wada JA editors. Kindling. vol. 3:New York: Raven Press; 1986;p. 73–87
  2. Aparicio LC, Candeletti S, Binashi A, Mazzuferri M, Di Benedetto M, Landuzzi D, et al. Kainate seizures increase Nociceptin/Orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. J. Neurochem. 2004;91:30–37
  3. Bertorelli R, Corradini L, Rafiq K, Tupper J, Calo G, Ongini E. Nociceptin and the ORL-1 ligand [Phe1psi (CH2-NH)Gly2]nociceptin(1-13)NH2 exert anti-opioid effects in the Freund's adjuvant-induced arthritic rat model of chronic pain. Br. J. Pharmacol. 1999;128:1252–1258
  4. Binaschi A, Zucchini S, Bregola G, Rodi D, Mazzuferi M, Reinscheid RK, et al. Delayed epileptogenesis in Nociceptin/Orphanin FQ deficient mice. Neuroreport. 2003;14:825–827
  5. Bregola G, Candeletti S, Romualdi P, Simonato M. Limbic seizures increase pronociceptin mRNA levels in the thalamic reticular nucleus. Neuroreport. 1999;10:541–546
  6. Bregola G, Zucchini S, Frigati L, Candeletti S, Romualdi P, Reinscheid R, et al. Involvement of the Neuropeptide Orphanin FQ/Nociceptin in kainate and kindling seizures and epileptogenesis. Epilepsia. 2002;43:18–19
  7. Bregola G, Zucchini S, Rodi D, Binaschi A, D’Addario C, Landuzzi D, et al. Involvement of the neuropeptide Nociceptin/Orphanin FQ in kainate seizures. J. Neurosci. 2002;22:10030–10038
  8. Calo G, Rizzi A, Marzola G, Guerrini R, Salvadori S, Beani L, et al. Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay. Br. J. Pharmacol. 1998;125:373–378
  9. Calo G, Guerrini R, Bigoni R, Rizzi A, Marzola G, Okawa H, et al. Characterization of [Nphe1]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist. Br. J. Pharmacol. 2000;129:1183–1193
  10. Chiou LC, Liao YY, Fan PC, Kuo PH, Wang CH, Riemer C, et al. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr. Drug Targets. 2007;8:117–135
  11. Clarke S, Chen Z, Hsu MS, Pintar J, Hill R, Kitchen I. Quantitative autoradiographic mapping of the ORL1, mu-, delta- and kappa-receptors in the brains of knockout mice lacking the ORL1 receptor gene. Brain Res. 2001;906:13–24
  12. Engel JJ, Ackermann RF. Interictal EEG spikes correlate with decreased, rather than increased, epileptogenicity in amygdaloid kindled rats. Brain Res. 1980;2:543–548
  13. Engel JJ, Rocha L. Interictal behavioral disturbances: a search for molecular substrates. Epilepsy Res. 1992;9:341–350
  14. Feng Y, Chao DM, Li WM, Cao YX, Wang YQ, Wu GC. Inhibition of nociceptin/orphanin FQ on penicillin-induced seizures in rats. Brain Res. 2004;1020:214–219
  15. Fischer A, Undem BJ. Naloxone blocks endomorphin-1 but not endomorphin-2 induced inhibition of tachykinergic contractions of guinea-pig isolated bronchus. Br. J. Pharmacol. 1999;127:605–608
  16. Frenk H, Engel JJ, Ackermann RF, Shavit Y, Liebeskind JC. Endogenous opioids may mediate post-ictal behavioral depression in amygdaloid-kindled rats. Brain Res. 1979;167:435–440
  17. Grisel JE, Mogil JS, Belknap JK, Grandy DK. Orphanin FQ acts as a supraspinal, but not a spinal, anti-opioid peptide. Neuroreport. 1996;7:2125–2129
  18. Gutierrez R, Leff P, Romo-Parra H, Acevedo R, Antón B. Orphanin-FQ/Nociceptin inhibits kindling epileptogenesis and enhances hippocampal feed-forward inhibition. Neuroscience. 2001;105:325–333
  19. Hashimoto Y, Calo G, Guerrini R, Smith G, Lambert DG. Effects of chronic nociceptin/orphanin FQ exposure on cAMP accumulation and receptor density in Chinese hamster ovary cells expressing human nociceptin/orphanin FQ receptors. Eur. J. Pharmacol. 2002;449:17–22
  20. Jenck F, Moreau JL, Martin JR, Kilpatrick GJ, Reinscheid RK, Monsma FJJ, et al. Orphanin FQ acts as an anxiolytic to attenuate behavioral responses to stress. Proc. Natl. Acad. Sci. U.S.A. 1997;94:14854–14858
  21. Jenck F, Wichmann J, Dautzenberg FM, Moreau JL, Ouagazzal AM, Martin JR, et al. A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc. Natl. Acad. Sci. U.S.A. 2000;97:4938–4943
  22. Kest B, Hopkins E, Palmese CA, Chen ZP, Mogil JS, Pintar JE. Morphine tolerance and dependence in nociceptin/orphanin FQ transgenic knock-out mice. Neuroscience. 2001;104:217–222
  23. Löscher W, Cramer S, Ebert U. Limbic epileptogenesis alters the anticonvulsant efficacy of phenytoin in Sprague–Dawley rats. Epilepsy Res. 1998;31:175–186
  24. Manabe T, Noda Y, Mamiya T, Katagiri H, Houtani T, Nishi M, et al. Facilitation of long-term potentiation and memory in mice lacking nociceptin receptors. Nature. 1998;394:577–581
  25. Mathis JP, Goldberg IE, Rossi GC, Leventhal L, Pasternak GW. Antinociceptive analogs of orphanin FQ/nociceptin(1-11). Life Sci. 1998;63:161–166
  26. Mathis JP, Goldberg IE, Letchworth SR, Ryan-Moro JP, Pasternak GW. Identification of a high-affinity orphanin FQ/nociceptin(1-11) binding site in mouse brain. Synapse. 1999;34:181–186
  27. Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature. 1995;377:532–535
  28. Mitsushima D, Funabashi T, Kimura F. Fos expression in gonadotropin-releasing hormone neurons by naloxone or bicuculline in intact male rats. Brain Res. 1999;839:209–212
  29. Mogil JS, Grisel JE, Reinscheid RK, Civelli O, Belknap JK, Grandy DK. Orphanin FQ is a functional anti-opioid peptide. Neuroscience. 1996;75:333–337
  30. Mogil JS, Grisel JE, Zhangs G, Belknap JK, Grandy DK. Functional antagonism of mu-, delta- and kappa-opioid antinociception by orphanin FQ. Neurosci. Lett. 1996;214:131–134
  31. Mogil JS, Pasternak GW. The molecular and behavioral pharmacology of the orphanin FQ/nociceptin peptide and receptor family. Pharmacol Rev. 2001;53:381–415
  32. Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 1994;341:33–38
  33. Neal CRJ, Mansour A, Reinscheid R, Nothacker HP, Civelli O, Akil H, et al. Opioid receptor-like (ORL1) receptor distribution in the rat central nervous system: comparison of ORL1 receptor mRNA expression with (125)I-[(14)Tyr]-orphanin FQ binding. J. Comp. Neurol. 1999;412:563–605
  34. Nobrega JN, Kish SJ, Burnham WM. Autoradiographic analysis of benzodiazepine binding in entorhinal-kindled rat brains. Brain Res. 1989;498:315–322
  35. Ouagazzal AM, Moreau JL, Pauly-Evers M, Jenck F. Impact of environmental housing conditions on the emotional responses of mice deficient for nociceptin/orphanin FQ peptide precursor gene. Behav. Brain Res. 2003;144:11–17
  36. Ozsoy HZ, Thakker DR, Standifer KM. Orphanin FQ/nociceptin potentiates [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin-Induced mu-opioid receptor phosphorylation. Mol. Pharmacol. 2005;68:447–456
  37. Pan YX, Xu J, Wan BL, Zuckerman A, Pasternak GW. Identification and differential regional expression of KOR-3/ORL-1 gene splice variants in mouse brain. FEBS Lett. 1998;435:65–68
  38. Pan Z, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron. 2000;26:515–522
  39. Paxinos G, Watson C. The Rat Brain in Stereoctaxic Coordinates. fourth ed.. USA: Academic Press; 1998;
  40. Racine RJ. Modification of seizure activity by electrical stimulation. II. Motor seizure. Electroencephalogr. Clin. Neurophysiol. 1972;32:281–294
  41. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, et al. Orphanin FQ: a neuropeptide that activates an opioid like G protein-coupled receptor. Science. 1995;270:792–794
  42. Rocha L, Ackermann RF, Engel JJ. Effects of chronic morphine pretreatment on amygdala kindling development, postictal seizure and suppression and benzodiazepine receptor binding in rats. Epilepsy Res. 1996;23:225–233
  43. Rubaj A, Zgodzinski W, Gustaw K, Sieklucka-Dziuba M. Nociceptin, OP4 receptor ligand in different models of experimental epilepsy. Peptides. 2002;23:497–505
  44. Shin C, Pedersen HB, McNamara JO. Gamma-aminobutyric acid and benzodiazepine receptors in the kindling model of epilepsy: a quantitative radiohistochemical study. Neuroscience. 1985;5:2696–2701
  45. Wang HL. A conserved arginine in the distal third intracellular loop of the mu-opioid receptor is required for G protein activation. J. Neurochem. 1999;72:1307–1314
  46. Wang HL, Hsu CY, Huang PC, Kuo YL, Li AH, Yeh TH, et al. Heterodimerization of opioid receptor-like 1 and mu-opioid receptors impairs the potency of micro receptor agonist. J. Neurochem. 2005;92:1285–1294

PII: S0920-1211(07)00248-3

doi: 10.1016/j.eplepsyres.2007.08.007

Epilepsy Research
Volume 77, Issue 2 , Pages 75-84 , December 2007

Article Tools

* Image Usage & Resolution